Immuron Ltd — Regulatory Filings 2006

Nov 9, 2006

November 10th, 2006

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Please find herewith a company announcement "U.S. Distributor Appointed for Travelan" for release and distribution to the market immediately.

Yours sincerely

CONOR GRAHAM Managing Director & CEO

US Distributor appointed for Travelan Australian developed therapeutic set for US sales early 2007

Australian biopharmaceutical company Anadis Limited (ASX:ANX) is pleased to announce the appointment of Cynacon / OCuSOFT Inc as the US distributor for Travelan. "We are extremely excited about this partnership", notes Cynthia Barratt, President and CEO of CYNACON / OCuSOFT. "OCuSOFT has been looking for the right opportunity to utilize our retail distribution channels and Travelan will make for a great fit". Ms Barratt goes on to say.

The US Market

The US market is very significant – with more than 22 million US travellers per year to "High Risk" areas. Medical statistics show on average over 40% of travellers will be somehow affected by Travellers' Diarrhoea.

Approval for Sales

After analysing a significant number of distribution opportunities, the management of Anadis believe the track record and sales force of Cynacon / OCuSOFT to be the optimal solution in order to begin distribution of Travelan to the US.

Due to the size and complexity of the US market - and the opportunity it presents; Anadis carried out an extensive review of partner opportunities over the past 12 months. It is therefore with great pleasure that we now announce our exclusive distributor for the USA - Cynacon/OCuSOFT Inc.

Travelan has already been assessed in the United States and given the green light to be sold into the North American market, as Travelan is in compliance with all US Federal and State regulations for sale in the OTC, Medical Food category.

Cynacon / OCuSOFT Inc.

The company is a successful, medium sized, medical distribution and research company established in 1986 based in Houston, Texas. It is well regarded and has long-standing commercial relationships with the major drug-store retailers throughout the USA (such as Walgreens, CVS, Wal-Mart etc).

The Company is currently a key player in ophthalmic medicine and markets its proprietary brands of OTC and prescription products nationally. Cynacon / OCuSOFT is excited to partner with Anadis in establishing a significant foothold in the growing and lucrative gastrointestinal disease market in the USA.

To support the opportunity offered the Cynacon/OCuSOFT will establish a key opinion leader / gastro technical advisory board to support the business development of Anadis' Travelan and other future antibody-based gastrointestinal products.

Visit www.ocusoft.com for more information.

Travelan - Natural and Effective

Travelan, a natural, clinically proven therapy is a revolutionary over-the-counter (OTC) preparation scientifically and clinically proven to significantly reduce the risk of getting the medical condition known as travellers' diarrhoea.

Travelan is prepared from naturally derived antibodies against 13 strains of E. coli that are the most common cause of travellers' diarrhoea. Travelan is high in antibodies that bind to certain intestinal bacteria and bacterial by-products, and is a not an antibiotic preparation - therefore not associated with the usual negative antibiotic side effects.

Travelan is a natural product that will enable travel with reduced fear of becoming ill due to exposure to E. coli bacteria. In hospital clinical trials in the US and Europe, Travelan has shown up to 90% protection against Enterotoxigenic E. coli (ETEC), the main cause of Travellers' Diarrhoea.

Potential Additional Gastrointestinal Indications for Travelan

Anadis will be investigating the use of Travelan for additional gastrointestinal therapeutic indications as a result of positive clinical feedback from a number of healthcare providers including medical specialists.

Reports to the company indicate that a number of patients with a range of gastrointestinal conditions, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and ulcerative colitis, have experienced an improvement in some their symptoms (e.g. diarrhoea) whilst taking Travelan to reduce their risk of travellers' diarrhoea.

Travellers Diarrhoea

Travellers' diarrhoea (otherwise known as Delhi Belly, Montezuma's Revenge, Tourist Trots and The Flux etc) is described as the number one health problem for international travellers, in terms of frequency and economic impact. Travellers' diarrhoea is normally accompanied by other clinical features such as nausea, bloating, abdominal cramps and fever. Travelan significantly reduces the risk of being affected in the first instance.

Visit our websites: www.anadis.com.au and www.travelan.com

Anadis - Delivering On The Promise Of Biotechnology

About Anadis Limited:

Anadis, a Melbourne based biopharmaceutical company is focused on Nutraceutical and Pharmaceutical research and development. Anadis is a specialist in the development of bovine colostrum derived products for therapeutic use in humans. Projects include:

Anadis' first commercialised product: Travelan is a natural product, which significantly decrease the risk of the medical condition known as Travellers Diarrhoea and the symptoms of gastrointestinal disorders. Travelan is a colostrum preparation, against the common strains of $E_{\text{col}}i$ – the most common cause of Travellers.

Travelan has received a "Green Light' for sales in the US and a distributor in Canada has been appointed. Travelan is being considered for other markets including: Singapore, India, Korea, United Arab Emirates, Thailand, Malaysia. South Africa and the UK and EU.

Travelan has recently been potentially identified for additional gastrointestinal indications including Irritable Bowel Syndrome IBS and Inflammatory Bowel Disorder IBD.

For more information please visit www.travelan.com

EV-71 - a bioactive protein based preventative product against Enterovirus 71, a debilitating polio like disease, is one of the viruses that causes 'hand, foot and mouth' or 'slapped cheek' disease. A significant proportion of younger children effected can develop nervous signs such as fits, paralysis and Enterovirus 71 has the potentially to be fatal. Anadis is now preparing colostrum antibodies for commercialisation in an anti-EV71 preventative, set to begin marketing in Taiwan during the northern hemisphere summer of 2007.

A set of Bio-Defence and Respiratory Protection technologies, a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma.

This project is expanding to examine the use of antibodies in providing respiratory protection against Influenza virus

Bio-Shield 10 a range of "bio-shielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market.

Development into an Immune Stimulating Infant Formula is underway, initially destined for the Asian market.

Pyloran, which has been clinically proven to reduce levels of H.pylori bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine.

For further information, please contact:

Conor Graham - Chief Executive Officer Email: $conor.g@anadis.com.au$ +61 3 9358 6388 Arie Nudel - Investor Relations Email: arie.n@anadis.com.au +61 3 9358 6388